Volume 15 Supplement 1

Proceedings of the International Cancer Imaging Society (ICIS) 15th Annual Teaching Course

Open Access

Chemotherapy induced cardiomyopathy: an overview, imaging features, and future prospective

  • D Divito1,
  • M Bondin1,
  • SK Kirschner1,
  • J Stojanovska1,
  • E Ibrahim1 and
  • L Frank1Email author
Cancer Imaging201515(Suppl 1):P21

https://doi.org/10.1186/1470-7330-15-S1-P21

Published: 2 October 2015

Learning objectives

To review the spectrum of imaging findings of chemotherapy- induced cardiomyopathy in correlation with most common cytotoxic drugs and regimens.

Content organisation

Cardio toxic effect of chemotherapy is a well-recognised problem in cancer patients. Cardio toxicity depends on multiple predisposing factors, specific components of the chemotherapy regimen, length of treatment, and dosage.

We will present the spectrum of most common cardiotoxic chemotherapy agents and their combinations, specific effects on the myocardium, and imaging features of cardiomyopathies induced by chemotherapy.

We will review pathophysiology of chemotherapy induced cardiomyopathy including:

  • Dose dependent cardiomyopathy

  • Predisposing conditions –diabetes, presence of coronary artery disease, age.

  • Potential reversibility

We will discuss imaging characteristics of chemotherapy induced cardiomyopathy

  • Imaging modalities (Echocardiography, Cardiac MR, and MUGA)

  • Importance of monitoring cardiac function during and after treatment

  • Distribution of late Gadolinium enhancement (LGE)

  • Emerging technologies for early diagnosis of cardiomyopathy in cancer patients

Conclusions

Chemotherapy induced cardiomyopathy is a common problem among cancer patients, increasing long term morbidity and mortality and often leading to disability. Patients receiving chemotherapy treatment, particularly cardio toxic agents, should be routinely assessed for cardiac function to diagnose cardiomyopathy during the early phase of treatment and to prevent development of irreversible heart failure.

Authors’ Affiliations

(1)
University of Texas Medical Branch

Copyright

© Divito et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement